BioSpace News Archive

Policy

EU Orders Illumina to Divest Grail After Years of Regulatory Challenges

The European Commission on Thursday ordered Illumina to divest Grail, opening the next chapter in the years-long regulatory saga. Illumina is reviewing the order, Reuters reported.

October 11, 2023
·
3 min read
·
Tristan Manalac
Business

The Many Lives of Alexandria Forbes

The MeiraGTx founder and CEO, now on her third career, didn’t take a typical path.

October 11, 2023
·
4 min read
·
Nadia Bey
Deals

Massachusetts Biopharma Job Growth Surpasses that of Other States: Report

An increase in funding share and available lab space helps to keep the Bay State’s biotech and pharma sectors strong.

October 11, 2023
·
4 min read
·
Charlotte LoBuono
Drug Development

Novo Ends Semaglutide Kidney Study Early Due to Strong Efficacy Signals

Following the recommendations of an independent Data Monitoring Committee, Novo Nordisk has halted a Phase III kidney outcomes study of semaglutide ahead of schedule due to strong efficacy signals.

October 11, 2023
·
2 min read
·
Tristan Manalac
Business

Sana Downsizes Staff by 29%, Refocuses on Ex Vivo Cell Therapy Platform

The biotech is laying off about 29% of its employees and will focus its resources on the company’s hypoimmune platform. The latest downsizing follows a previous round of layoffs in August 2023.

October 11, 2023
·
2 min read
·
Tristan Manalac
Drug Development

Opinion: Interest in RNA Editing Accelerates as Therapies Approach the Clinic

The next frontier in RNA therapies, RNA editing has the potential to treat both genetic and common disorders, and the technology is rapidly expanding beyond the liver.

October 11, 2023
·
4 min read
·
Gerard Platenburg
Drug Development

Roche’s Subcutaneous Ocrevus Rivals IV Formulation in Phase III MS Trial

The subcutaneous version of its blockbuster multiple sclerosis drug notched a victory in a key late-stage study. Roche will submit the OCARINA II data to global health authorities in the coming months.

October 11, 2023
·
2 min read
·
Kate Goodwin
Genetown

Allurion Completes Enrollment in Pivotal AUDACITY Trial for the Allurion Balloon

Allurion Technologies, Inc. today announced the completion of patient enrollment in its AUDACITY trial. AUDACITY is a randomized, pivotal controlled trial designed to support U.S. Food and Drug Administration (FDA) approval of the Allurion Balloon.

October 11, 2023
·
5 min read
Genetown

Charles River Laboratories Achieves 90% Renewable Electricity Globally, Announces Progress on Environmental Goals

Charles River Laboratories International, Inc. (NYSE: CRL) today announced that, while working toward previously announced environmental goals, the Company has achieved 90 percent renewable electricity globally.

October 11, 2023
·
4 min read
Genetown

Lucy Therapeutics Expands Cutting-Edge Medical Research Program

Lucy Therapeutics (LucyTx) has secured new funding from the International Rett Syndrome Foundation (IRSF) to invest in pioneering treatments for children and adults living with Rett syndrome, and to grow LucyTx’s groundbreaking treatment platform.

October 11, 2023
·
4 min read